摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2(RS)-benzyloxycarbonylamino-4(RS)-(napth1-yl)pentanoic acid | 1050444-84-2

中文名称
——
中文别名
——
英文名称
2(RS)-benzyloxycarbonylamino-4(RS)-(napth1-yl)pentanoic acid
英文别名
2-benzyloxy-carbonylamino-4-(napth-1-yl)pentanoic acid;4-Naphthalen-1-yl-2-(phenylmethoxycarbonylamino)pentanoic acid
2(RS)-benzyloxycarbonylamino-4(RS)-(napth1-yl)pentanoic acid化学式
CAS
1050444-84-2
化学式
C23H23NO4
mdl
——
分子量
377.44
InChiKey
HBUKOYQZLWSHEY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    28
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    75.6
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • [EN] PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES PEPTIDIQUES EN TANT QU'INHIBITEURS DE LA PROTEASE A CYSTEINE
    申请人:AXYS PHARM INC
    公开号:WO2004000838A1
    公开(公告)日:2003-12-31
    The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    本发明涉及一种抑制半胱蛋白酶的化合物,特别是卡特普辛B、K、L、F和S,因此在治疗由这些蛋白酶介导的疾病方面具有用途。本发明涉及包含这些化合物的药物组合物以及制备它们的方法。
  • [EN] AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES AMIDINO SERVANT D'INHIBITEURS DE PROTEASES A CYSTEINE
    申请人:AXYS PHARMACEUTICALS
    公开号:WO2004108661A1
    公开(公告)日:2004-12-16
    The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    本发明涉及一种抑制半胱蛋白酶的化合物,特别是包括B、K、L、F和S半胱蛋白酶,因此在治疗由这些蛋白酶介导的疾病方面具有用处。本发明涉及包含这些化合物的药物组合物以及其制备方法。
  • [EN] HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES CONTENANT UN HALOALKYLE UTILISE COMME INHIBITEURS DE CYSTEINE PROTEASE
    申请人:AXYS PHARM INC
    公开号:WO2005028454A1
    公开(公告)日:2005-03-31
    The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. Pharmaceutical compositions comprising these compounds and their use are also disclosed.
    该应用程序针对式(I)的卤代烷基取代化合物,其中R1、R1a、R2、R3、R4'和E如索权中所定义。这些化合物是半胱蛋白酶抑制剂,特别是卡托普斯蛋白酶B、K、L、F和S,因此可用于治疗由这些蛋白酶介导的疾病。还公开了包含这些化合物的药物组合物及其用途。
  • Cyanomethyl derivatives as cysteine protease inhibitors
    申请人:Graupe Michael
    公开号:US20060122184A1
    公开(公告)日:2006-06-08
    The present invention is directed to cyanomethyl derivatives that are inhibitors of cysteine protease, in particular, cathepsin B, K, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    本发明涉及甲基衍生物,其是半胱蛋白酶抑制剂,特别是对于B、K、F和S型的卡特普辛,因此可用于治疗由这些蛋白酶介导的疾病。本发明还涉及包含这些化合物的制药组合物和其制备过程。
  • Cysteine protease inhibitors
    申请人:Graupe Michael
    公开号:US20050288336A1
    公开(公告)日:2005-12-29
    The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    本发明涉及一种抑制半胱蛋白酶的化合物,特别是cathepsin B、K、L、F和S,因此可用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和制备它们的过程。
查看更多